FDA Grants Fast Track Designation to ImmVira's MVR-T3011 IT for Advanced Head and Neck Cancer

18 March 2024 | Monday | News

This pivotal recognition underscores the potential of MVR-T3011 IT, an innovative oncolytic virus therapy, to address the critical treatment gap for patients with recurrent or metastatic HNSCC
Image Source : Public Domain

Image Source : Public Domain

ImmVira's groundbreaking oncolytic virus therapy, MVR-T3011 IT intratumoral injection, has been awarded Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This significant recognition comes in response to the urgent need for new therapies for HNSCC, particularly for patients who have seen disease progression after platinum-based chemotherapy and prior anti-PD1/PDL1 therapy.

The decision by the FDA to grant Fast Track designation is a testament to MVR-T3011 IT's promising potential to fill the existing treatment void for HNSCC, a cancer type witnessing rising incidence rates and a significant recurrence and metastasis challenge. Despite advances in immunotherapy, the effectiveness of current treatments remains limited to a small percentage of patients, highlighting a critical demand for innovative treatment approaches.

The Phase I/II trials of MVR-T3011 IT, conducted in both the United States and China, have shown encouraging results in efficacy, safety, and durability of response in HNSCC patients, particularly those who have not benefited from existing immune checkpoint inhibitors. This therapy aims to not only target the tumor directly but also to modulate the tumor microenvironment to enhance immune responses against cancer cells.

Grace Guoying Zhou, Chairwoman and CEO of ImmVira, expressed enthusiasm about the FDA's recognition of the potential of MVR-T3011 IT to meet the significant unmet medical needs in HNSCC treatment. She highlighted the importance of this milestone in accelerating the development and availability of MVR-T3011 IT to patients in need of novel therapeutic options.

MVR-T3011 IT represents a novel approach in the fight against HNSCC, combining the unique capabilities of oncolytic herpes simplex virus (oHSV) technology with the power of immune modulation through the integration of PD-1 antibody and IL-12 genes. This combination is designed to attack tumor cells directly while simultaneously boosting the body's immune response to the cancer, offering hope for better outcomes for patients facing this challenging disease.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in